Literature DB >> 10210328

Involvement of CD44 variant isoform v10 in progenitor cell adhesion and maturation.

M Rösel1, S Khaldoyanidi, V Zawadzki, M Zöller.   

Abstract

CD44 has been described repeatedly to be involved in hematopoiesis. Here, we addressed the question of functional activity of CD44 variant isoform v10 (CD44v10) in progenitor cell maturation by in vivo and in vitro blocking studies with a monoclonal antibody and a receptor globulin. We became interested in this question by the observation that CD44v10 is expressed, although at a low level, on a subpopulation of bone marrow cells. Flow cytometry revealed that 15%-20% of hematopoietic cells in the fetal liver and 25%-35% of bone marrow cells in adult mice were CD44v10 positive. The majority of CD44v10+ cells was HSA+/J11d+ and CD43+. CD44v10 was not detected on CD4+, CD8+, IgM+, or IgD+ cells. A CD44v10 receptor globulin did not bind to hematopoietic progenitor cells, but to stromal elements. The CD44v10-CD44v10 ligand interaction had a major impact on the adhesion of progenitor cells to stromal elements. When healthy animals received repeated injections of either anti CD44v10 or the CD44v10 receptor globulin, committed progenitors were mobilized and significantly augmented numbers were recovered in the spleen and the peripheral blood. Furthermore, the CD44v10-CD44v10 ligand interaction, which had no impact on progenitor expansion, influenced progenitor maturation, particularly of the B-cell lineage. Although the nature of the CD44v10 ligand remains to be explored, the supportive role of CD44v10 in progenitor maturation and, importantly, the efficient mobilization of progenitor cells by anti-CD44v10 and a CD44v10 receptor globulin could be of clinical benefit in peripheral blood stem cell transplantation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10210328     DOI: 10.1016/s0301-472x(98)00082-4

Source DB:  PubMed          Journal:  Exp Hematol        ISSN: 0301-472X            Impact factor:   3.084


  8 in total

1.  Hyaluronan Depolymerization by Megakaryocyte Hyaluronidase-2 Is Required for Thrombopoiesis.

Authors:  Aaron C Petrey; Dana R Obery; Sean P Kessler; Bruno Flamion; Carol A de la Motte
Journal:  Am J Pathol       Date:  2016-07-08       Impact factor: 4.307

Review 2.  Hyaluronan in inflammatory bowel disease: Cross-linking inflammation and coagulation.

Authors:  Aaron C Petrey; Carol A de la Motte
Journal:  Matrix Biol       Date:  2018-03-21       Impact factor: 11.583

3.  The CD44 receptor is a molecular predictor of survival in ovarian cancer.

Authors:  L Rodríguez-Rodríguez; I Sancho-Torres; C Mesonero; D G Gibbon; W J Shih; G Zotalis
Journal:  Med Oncol       Date:  2003       Impact factor: 3.064

Review 4.  Cancer stem cells in basic science and in translational oncology: can we translate into clinical application?

Authors:  Axel Schulenburg; Katharina Blatt; Sabine Cerny-Reiterer; Irina Sadovnik; Harald Herrmann; Brigitte Marian; Thomas W Grunt; Christoph C Zielinski; Peter Valent
Journal:  J Hematol Oncol       Date:  2015-02-25       Impact factor: 17.388

5.  CD44 standard and CD44v10 isoform expression on leukemia cells distinctly influences niche embedding of hematopoietic stem cells.

Authors:  Ulrike Erb; Amelie Pajip Megaptche; Xiaoyu Gu; Markus W Büchler; Margot Zöller
Journal:  J Hematol Oncol       Date:  2014-03-31       Impact factor: 17.388

Review 6.  Mobilized peripheral blood: an updated perspective.

Authors:  Darja Karpova; Michael P Rettig; John F DiPersio
Journal:  F1000Res       Date:  2019-12-20

7.  DNA aptamers against exon v10 of CD44 inhibit breast cancer cell migration.

Authors:  Joji Iida; Rebecca Clancy; Jesse Dorchak; Richard I Somiari; Stella Somiari; Mary Lou Cutler; Richard J Mural; Craig D Shriver
Journal:  PLoS One       Date:  2014-02-19       Impact factor: 3.240

8.  Co-culture with mesenchymal stromal cells increases proliferation and maintenance of haematopoietic progenitor cells.

Authors:  Thomas Walenda; Simone Bork; Patrick Horn; Frederik Wein; Rainer Saffrich; Anke Diehlmann; Volker Eckstein; Anthony D Ho; Wolfgang Wagner
Journal:  J Cell Mol Med       Date:  2009-05-11       Impact factor: 5.310

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.